



Australian Government

Department of Health and Ageing

SCHEDULE OF PHARMACEUTICAL BENEFITS FOR DENTAL PRACTITIONERS

This Schedule is also available on the internet at
www.pbs.gov.au

**EFFECTIVE 1 January 2011 -
31 January 2011
(ALL PREVIOUS EDITIONS CANCELLED)**

© Commonwealth of Australia 2011

ISSN 1037-3675

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

This Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These arrangements operate under the *National Health Act 1953*. However, at the time of printing, the relevant legislation giving authority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment for the supply of pharmaceutical benefits. The legislation is available from the Federal Register of Legislative Instruments website at <http://www.frli.gov.au>.

The information is not intended to give or replace any legal, medical, dental or optometrical advice. This document is not a legal document and does not constitute legal advice. Neither the information nor this document can be relied upon without first seeking and obtaining independent legal, medical, dental or optometrical advice beforehand. To the extent permitted by law, the Commonwealth of Australia will not be held responsible, nor accept any liability (whether arising out of negligence or otherwise), for any injury, damages, costs, expenses and losses suffered or incurred by a person where such a person has relied on this document or used the information in it as legal, medical, dental or optometrical advice.

CONTENTS

SUMMARY OF CHANGE	4
Section 1 – Explanatory Notes	5
Introduction.....	5
1. The Schedule — Where to Find What.....	5
<i>Section 1.....</i>	<i>5</i>
<i>Section 2.....</i>	<i>5</i>
2. Prescribing Medicines — Information for Dentists	5
<i>Eligible prescribers</i>	<i>5</i>
<i>PBS prescription forms.....</i>	<i>5</i>
<i>Preparing general prescriptions.....</i>	<i>6</i>
<i>Restrictions.....</i>	<i>6</i>
<i>Maximum quantities.....</i>	<i>6</i>
<i>Urgent cases.....</i>	<i>7</i>
3. Patient Charges	7
<i>Type of patient</i>	<i>7</i>
<i>What patients pay.....</i>	<i>7</i>
4. RPBS Dental Prescribing	8
Addresses — Medicare Australia	9
INDEX OF MANUFACTURERS' CODES	10
THERAPEUTIC INDEX.....	14
SECTION 2	17
<i>Symbols used in the Schedule</i>	<i>18</i>
GENERIC/PROPRIETARY INDEX	48

PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 January 2011. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

SUMMARY OF CHANGES

ALTERATIONS

Alterations — Proprietary Name

From:

5235M **Tramadol hydrochloride**, Tablet 150 mg (twice daily sustained release), (*Tramahexal SR*)

To:

5235M **Tramadol hydrochloride**, Tablet 150 mg (twice daily sustained release), (*Tramadol Sandoz SR*)

Section 1 – Explanatory Notes

Introduction

These Explanatory Notes are provided to help dentists work within the Australian Government's Pharmaceutical Benefits Scheme (PBS).

The PBS is a system of subsidising the cost of most prescription medicines. The subsidies are available to all Australian residents and eligible foreign visitors, i.e., people from countries which have Reciprocal Health Care Agreements with Australia. These countries are the United Kingdom, Ireland, New Zealand, Malta, Italy, Sweden, the Netherlands, Finland, Norway and Belgium.

The aim of the PBS, which has been in operation since 1948, is to provide reliable and affordable access to a wide range of necessary medicines.

The Schedule of Pharmaceutical Benefits – referred to throughout as the 'Schedule' – lists all of the medicines available under the PBS, and explains how they can be used in order to be subsidised.

The Schedule is produced monthly by the Australian Department of Health and Ageing (effective on the first day of each month).

It is vital therefore that dentists remain up to date with information on which medicines are included in or excluded from the Schedule, whether restrictions apply to the medicines, and how much patients should pay. Queries relating to the PBS can be made to the Pharmaceutical Branch in the State offices of Medicare Australia (telephone 132 290 Mondays to Fridays, during business hours). Queries relating to the Repatriation Pharmaceutical Benefits Scheme (RPBS) can be made to the State offices of the Department of Veterans' Affairs (DVA) (telephone 1800 552 580).

1. The Schedule — Where to Find What

The Schedule of Pharmaceutical Benefits is divided into sections. At the start of the Schedule, immediately after the table of contents, is a summary of any changes to listed items.

The last pages of the Schedule provide a generic/proprietary index of PBS and RPBS ready-prepared items.

Section 1

Section 1 is what you are reading, the Explanatory Notes. It outlines the correct way to prescribe pharmaceutical benefits, patient charges and who qualifies for concessions. This is followed by a list of Medicare Australia contacts and addresses, then an index of manufacturers' codes.

Section 2

This section lists ready-prepared items, and includes the form, manner of administration, brand and brand equivalents that may be prescribed, and the maximum quantity for each item.

Any medicines that have restrictions on how they can be prescribed are printed in ***bold italics***. Items appearing in more than one therapeutic group are cross-referenced.

Section 2 SYMBOLS USED IN THE SCHEDULE explains symbols used throughout the Schedule.

The use of 'NOTE' in this section is used to clarify how some pharmaceutical benefits should be prescribed.

The use of 'CAUTION' is to warn of known adverse reactions from, or precautions to be taken with, a particular pharmaceutical benefit. (The absence of a cautionary note does not imply reactions may not happen.)

2. Prescribing Medicines — Information for Dentists

Eligible prescribers

Pharmaceutical benefits can only be prescribed by dentists who are approved to work within the PBS.

PBS prescription forms

Standard PBS prescription forms are available from Medicare Australia for prescribing pharmaceutical benefits.

- *Personalised forms* – have the dentist's name, qualifications, practice address/es, telephone number and prescriber number.
- *Non-personalised (blank) forms* – are distributed for emergency supply only. Both forms for dentists are supplied free of charge.

Ordering forms

Dentists are asked not to over order. Getting the right amount of forms helps to reduce the cost to taxpayers and helps to reduce paper wastage. Also, the pads may deteriorate if stored over time.

Order forms for standard PBS prescription forms are available from Medicare Australia stationery officers. Contact details are listed in the front of the Schedule.

Orders for PBS prescription stationery will only be accepted by application in writing and through the channels mentioned above.

Preparing general prescriptions

Do's and don't's

A PBS prescription is only valid when it is written by an approved dentist for dental treatment only.

The prescription must be for the treatment of the person named on the PBS prescription. A PBS prescription may only be written for the treatment of one person.

A dentist cannot write more than one PBS prescription for the same pharmaceutical benefit for the same person on the same day.

Up to **three** pharmaceutical benefit items may be included on a single PBS prescription form, but pharmaceutical benefits and non-pharmaceutical benefits should not be listed together on the one PBS prescription form.

If an item has a particular manner of administration it may not, as a pharmaceutical benefit, be administered in any other way, e.g., an ophthalmic preparation may not be prescribed for topical use.

If an item is restricted, but the patient is not suffering from one of the specified conditions, it cannot be prescribed as a pharmaceutical benefit. The dentist should write the prescription either on a private prescription or on a standard prescription with 'PBS/RPBS' clearly struck out. It should also be endorsed 'non-PBS'.

A dentist cannot prescribe a narcotic drug for him/herself. In some States and Territories the prescribing of drugs of addiction by dentists is not permitted.

Dentists are issued with individual PBS prescription pads by Medicare Australia for their own use – these pads should not be used by other dentists, as this can cause confusion through incorrect pharmacy records.

Dentists are required to include their prescriber numbers on non-personalised PBS prescriptions.

The following admixtures are not pharmaceutical benefits:

- the admixture of two or more ready-prepared items listed in the Schedule; or
- the admixture of a non-pharmaceutical benefit item with a pharmaceutical benefit item.

Writing the PBS prescription

The following rules apply for writing PBS prescriptions:

- they must be written in indelible form (i.e., ink or ball-point pen) in the dentist's own handwriting (exceptions must be approved by Medicare Australia's Chief Executive Officer) either on the standard PBS prescription, or on paper approximately 18 cm x 12 cm, or they can be generated by computer on a form approved by Medicare Australia. For patient safety reasons, both the original and the duplicate must be legible;
- they must record the dentist's name, address and prescriber number, the patient's name, address and entitlement status (i.e. whether they are a 'concessional' or 'general' patient), and whether the prescription is under the PBS or RPBS;
- they should completely identify the pharmaceutical benefit by detailing the item, dose, form, strength, quantity and instructions for use;
- they should indicate where brand substitution is not permitted. PBS prescriptions must not be prepared using a computer prescribing program that contains a default which would result in all prescriptions being indicated as Brand Substitution Not Permitted;
- where 'solvent required' is included after the form, the volume and number of ampoules must be specified; and
- they must be signed by the dentist and dated. Forward or back dating is not permitted.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a dental practitioner providing dental services within a participating public hospital, may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

Restrictions

Pharmaceutical benefits listed in this Schedule fall into two broad categories:

Unrestricted benefits – which have no restrictions on their therapeutic uses; and

Restricted benefits – which can only be prescribed for specific therapeutic uses (they are noted as **restricted benefit**).

Maximum quantities

The maximum quantities allowed for PBS items are recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). Dentists cannot prescribe repeats.

PBS prescriptions can be for any quantity up to the maximum. It is not necessary to prescribe the maximum quantity if a lesser quantity is sufficient for the patient's needs. Please clearly indicate the number of tablets, capsules, etc. required, and **do not use** abbreviations such as 'Max. Qty', or 'M.Q.'

Urgent cases

In urgent cases and where State/Territory law allows, a dentist may telephone a pharmacist and ask that a PBS prescription be supplied. He/she must then forward the written PBS prescription and duplicate to the pharmacist within **seven days of the date of supply**.

3. Patient Charges

Type of patient

There are two types of PBS beneficiaries – general patients and concessional patients. General patients hold a Medicare card. Concessional patients hold a Medicare card and one of the following cards from Centrelink or the Department of Veterans' Affairs (DVA):

- Pensioner Concession Card
- Commonwealth Seniors Health Card
- Health Care Card
- Repatriation Health Card For All Conditions (gold) – concessional patients under RPBS
- Repatriation Health Card For Specific Conditions (white) – only regarded as concessional patients for RPBS prescriptions unless they hold a separate entitlement from Centrelink, otherwise they are general patients
- Repatriation Pharmaceutical Benefits Card (orange) – concessional patients under RPBS
- Safety Net Concession Card or Safety Net Entitlement Card are also issued by Medicare Australia.

Under the Reciprocal Health Care Agreements (RHCA), visitors from participating countries (see the introduction of this section for the list of countries) are treated as general patients – they do not have concessional entitlements. To receive pharmaceutical benefits, these visitors may need to present a temporary Medicare card or their passport.

What patients pay

Patient contribution

Under the PBS, the maximum cost for a pharmaceutical benefit item at a pharmacy is \$34.20 for general patients and \$5.60 for concessional patients (except where a brand premium applies).

Patients who have a Safety Net Entitlement Card receive PBS items for free, except where a brand premium applies.

The contribution rate for general patients as outpatients at public hospitals throughout Australia is \$27.40.

The exception is Queensland and hospitals participating in the pharmaceutical reforms where they pay the safety net value of an item when it is listed in the Schedule, or up to \$34.20 for items not listed in the Schedule. The public hospital pharmaceutical reforms enable participating public hospitals to prescribe and supply pharmaceutical medication from the PBS to outpatients and patients upon discharge.

The contribution rate for concessional patients in all public hospitals is \$5.60.

The supply of a pharmaceutical benefit or a Repatriation pharmaceutical benefit to a patient is a GST-free supply. Goods and services tax must not be included in the price charged to a patient for the supply of a benefit under the PBS or RPBS.

It is the patient's responsibility to meet any charge lawfully demanded by an approved pharmacist, otherwise supply may be refused.

The patient contribution rates are usually adjusted on 1 January each year in line with inflation.

Patient contributions for early supply of some PBS medicines

Prescriptions for some pharmaceutical benefits are not eligible for Safety Net benefits if resupplied within 20 days of a previous supply of the same pharmaceutical benefit for the same person under the PBS or the RPBS. (This is known as the 'Safety Net 20 day rule' which came into effect on 1 January 2006.)

Where a prescription is subject to the Safety Net 20 day rule, exclusion from Safety Net benefits has the following effects:

- the patient contribution does not count towards the Safety Net
- after the Safety Net threshold is reached, the usual patient payment amount for the corresponding entitlement level (not the Safety Net amount) applies.

There are no pharmaceutical benefits listed for prescribing by dentists that are subject to the Safety Net 20 day rule.

Brand premiums

Under the brand premium arrangements, Commonwealth reimbursement to pharmacists is based on the lowest-priced brand. Patients pay the difference for higher-priced brands, on top of their usual patient contribution.

The Schedule's brand premiums apply to maximum quantities. When a quantity is less than the maximum, the premium will be a fraction of the maximum quantity, using standard pricing rules.

Solvents

Where a solvent is prescribed as part of a pharmaceutical benefit, only one patient contribution is charged.

4. RPBS Dental Prescribing

Under Department of Veterans' Affairs (DVA) arrangements, financial responsibility for pharmaceutical benefits prescribed by a Local Dental Officer (LDO) is limited to the treatment to which holders of the following cards are entitled:

- a Gold Repatriation Health Card For All Conditions; or
- a White Repatriation Health Card For Specific Conditions; or
- an Orange Repatriation Pharmaceutical Benefits Card.

Where possible the LDO shall prescribe in accordance with the provisions governing dental prescribing under the PBS.

Prescriptions for PBS Dental Schedule items for Gold, White and Orange Card holders are to be dispensed at the PBS concessional rate. The card holder is required to meet the cost of any applicable brand premium.

When a non-PBS Dental Schedule item is prescribed for an eligible card holder, the LDO's private prescription form should be used. The dispensing pharmacist may charge the patient the full cost of the prescription. The patient may claim a refund for the full cost of a non-Schedule item from DVA if an itemised receipt (not a cash register receipt) and a copy of the prescription are provided.

Addresses — Medicare Australia

Medicare Australia has responsibility for the operational aspects of the Pharmaceutical Benefits Scheme (PBS). This responsibility covers the processing of pharmaceutical benefit and safety net claims, authority applications and supply of PBS stationery used by medical practitioners, participating dental practitioners and approved pharmacists.

Procedures for ordering prescription forms are set out in Introduction of this Schedule .

New South Wales and Australian Capital Territory

Pharmaceutical Benefits Branch
130 George Street
Parramatta NSW 2150

General and IME enquiries — Tel: 132 290

Orange Service Centre
189 Anson Street
Orange NSW 2800

General and IME enquiries — Tel: 132 290

Victoria

Pharmaceutical Branch
Level 10
595 Collins Street
Melbourne Vic 3000

General and IME enquiries — Tel: 132 290

Queensland

Pharmaceutical Services Branch
143 Turbot Street
Brisbane Qld 4000

General and IME enquiries — Tel: 132 290

South Australia and Northern Territory

Pharmaceutical Services Branch
209 Greenhill Road
Eastwood SA 5063

General and IME enquiries — Tel: 132 290

Western Australia

Pharmaceutical Benefits Branch
11th Floor, Bankwest Tower
108 St George's Terrace
Perth WA 6000

General and IME enquiries — Tel: 132 290

Tasmania

Pharmaceutical Branch
242 Liverpool Street
Hobart Tas 7000

General and IME enquiries — Tel: 132 290

National Program Management

Pharmaceutical Benefits Branch
Medicare Australia
134 Reed Street
Tuggeranong ACT 2900

Telephone — (02) 6124 6333

Website — www.medicareaustralia.gov.au Email — pbs@medicareaustralia.gov.au

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>	<i>Code</i>	<i>Manufacturer</i>
AB	Abbott Australasia Pty Ltd Sir Joseph Banks Corporate Park 32- 34 Lord Street Botany NSW 2019 Tel: (02) 9384 9700 Fax: (02) 9384 9800	BR	B. Braun Australia Pty Ltd Norwest Business Park 17 Lexington Drive Bella Vista NSW 2153 Tel: (02) 9629 0200 Fax: (02) 9629 0299
AF	Alphapharm Pty Limited Chase Building 2 Wentworth Park Road Glebe NSW 2037 Tel: (02) 9298 3999 Fax: (02) 9566 4686	BX	Baxter Healthcare Pty Limited 1 Baxter Drive Old Toongabbie NSW 2146 Tel: (02) 9848 1111 Fax: (02) 9848 1123
AL	Alphapharm Medical A Division of Alphapharm Pty Limited Chase Building 2 Wentworth Park Road Glebe NSW 2037 Tel: (02) 9298 3999 Fax: (02) 9566 4686	CH	Chem mart Pty Limited Level 7, 5 Queens Road Melbourne Vic 3004 Tel: (03) 9918 2500 Fax: (03) 9918 2006
AP	AstraZeneca Pty Ltd Alma Road North Ryde NSW 2113 Tel: (02) 9978 3500 Fax: (02) 9978 3700	CO	Chemists' Own Pty Ltd A member of Sigma Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2753
AS	Aspen Pharmacare Australia Pty Ltd First Floor 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540	CR	Pharmacor Limited 5/36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475
AV	Aventis Pharma Division of Sanofi- Aventis Australia Pty Limited Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000	CS	CSL Limited 45 Poplar Road Parkville Vic 3052 Tel: (03) 9389 1911 Fax: (03) 9388 2351
BF	Bellwether Pharma Ltd Suite 1, Level 1 1175 Toorak Road Camberwell Vic 3124 Tel: (03) 9809 7900 Fax: (03) 9809 7999	FK	Invida Australia Pty Ltd Level 8, 67 Albert Avenue Chatswood NSW 2067 Tel: (02) 9080 7200 Fax: (02) 9080 7201
BQ	Bristol-Myers Squibb Pharmaceuticals A Division of Bristol-Myers Squibb Australia Pty Ltd 556 Princes Highway Noble Park Vic 3174 Tel: (03) 9213 4000 Fax: (03) 9701 1518	FM	Fawns and McAllan Pty Ltd A member of Sigma Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2753

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>	<i>Code</i>	<i>Manufacturer</i>
GK	GlaxoSmithKline Australia Pty Ltd Level 4, 436-438 Johnston Street Abbotsford Vic 3067 Tel: (03) 9413 7300 Fax: (03) 8761 2410	KR	Kenral Division of Pharmacia Australia Pty Limited 59 Kirby Street Rydalmere NSW 2116 Tel: (02) 9848 3000 Fax: (02) 9848 3333
GM	Ascent Pharma Pty Ltd 151-153 Clarendon Street South Melbourne Vic 3205 Tel: 1800 678 302 Fax: (03) 8677 6666	LM	Link Medical Products Pty Ltd Level 1, Bridgepoint Centre 3 Brady Street Mosman NSW 2088 Tel: (02) 9960 0150 Fax: (02) 9960 0149
GN	Ascent Pharmaceuticals Limited 151-153 Clarendon Street South Melbourne Vic 3205 Tel: 1800 678 302 Fax: (03) 8677 6666	LN	Lennon Healthcare A Division of Aspen Pharmacare Australia Pty Ltd First Floor 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540
GQ	Generic Health Pty Ltd Suite 1, Level 1 1175 Toorak Road Camberwell Vic 3124 Tel: (03) 9809 7900 Fax: (03) 9809 7999	MD	Macarthur Research Division of Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9981 3229
GX	GenRx A Division of Apotex Pty Ltd 66 Waterloo Road North Ryde NSW 2113 Tel: (02) 8877 8333 Fax: (02) 8877 8377	MF	Mundipharma Pty Ltd Level 33, 50 Bridge Street Sydney NSW 2000 Tel: (02) 9231 7200 Fax: (02) 9223 0011
HH	Hospira Pty Ltd (David Bull Laboratories, Faulding Pharmaceuticals) Level 6, 390 St Kilda Road Melbourne Vic 3004 Tel: (03) 9868 0700 Fax: (03) 9868 0111	MI	Meditech Int. Pty Ltd Unit 5, 36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475
IA	iNova Pharmaceuticals (Australia) Pty Limited 9-15 Chilvers Road Thornleigh NSW 2120 Tel: (02) 9875 6333 Fax: (02) 9875 6416	NO	Novo Nordisk Pharmaceuticals Pty Ltd Level 3, 21 Solent Circuit Baulkham Hills NSW 2153 Tel: (02) 8858 3600 Fax: (02) 8858 3799
JC	Janssen-Cilag Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Tel: (02) 8875 3333 Fax: (02) 8875 3300	NV	Novartis Pharmaceuticals Australia Pty Ltd 54 Waterloo Road North Ryde NSW 2113 Tel: (02) 9805 3555 Fax: (02) 9887 4551

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>	<i>Code</i>	<i>Manufacturer</i>
PF	Pfizer Pty Limited 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9858 1347	SW	Sanofi-Aventis Australia Pty Ltd Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000
PK	Fresenius Kabi Australia Pty Limited 964 Pacific Highway Pymble NSW 2073 Tel: 1300 732 001 Fax: 1300 304 384	SZ	Sandoz Pty Ltd Level 4, Suite 7-19 100 Harris Street Pymont NSW 2009 Tel: (02) 9566 1500 Fax: (02) 9566 1458
PL	Phebra 332 Burns Bay Road Lane Cove NSW 2066 Tel: (02) 9420 9199 Fax: (02) 9420 9177	TS	Specialised Therapeutics Australia Pty Ltd Suite 3-4, 6 Westbrook Street East Kew Vic 3102 Tel: (03) 9859 1493 Fax: (03) 9859 6950
RA	Ranbaxy Australia Pty Limited Suite 4.02, Level 4 Building D 12-24 Talavera Road North Ryde NSW 2113 Tel: (02) 9647 1172 Fax: (02) 9647 1172	TW	Terry White Chemists Level 7, 5 Queens Road Melbourne Vic 3004 Tel: (03) 9918 2500 Fax: (03) 9918 2006
RC	Reckitt Benckiser (Australia) Pty Limited 44 Wharf Road West Ryde NSW 2114 Tel: (02) 9857 2000 Fax: (02) 9857 2004	TX	Apotex Pty Ltd 66 Waterloo Road North Ryde NSW 2113 Tel: (02) 8877 8333 Fax: (02) 8877 8377
RO	Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9971 7401	VT	Valeant Pharmaceuticals Australasia Pty Ltd Level 7, Suite 7.02 3 Rider Boulevard Rhodes NSW 2138 Tel: 1800 630 056 Fax: (02) 9743 4053
SH	Schering-Plough Pty Ltd Level 4, 66 Waterloo Road North Ryde NSW 2113 Tel: (02) 8988 8000 Fax: (02) 9852 7500	YM	Symbion Pharmacy Services Pty Ltd Level 7, 5 Queens Road Melbourne Vic 3004 Tel: (03) 9918 2000 Fax: (03) 9918 2006
SI	Sigma Pharmaceuticals (Australia) Pty Ltd A member of Sigma Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2753	YN	Mayne Pharma International Pty Ltd 1538 Main North Road Salisbury SA 5106 Tel: (08) 8209 2666 Fax: (08) 8281 6998

Index of Manufacturers' Codes

<i>Code</i>	<i>Manufacturer</i>
-------------	---------------------

YT	Mayne Products Pty Ltd 1538 Main North Road Salisbury SA 5106 Tel: (08) 8209 2666 Fax: (08) 8281 6998
----	---

ZP	Spirit Pharmaceuticals Pty Ltd 117 Harrington Street The Rocks Sydney NSW 2000 Tel: (02) 9251 1088 Fax: (02) 9251 1099
----	--

<i>Code</i>	<i>Manufacturer</i>
-------------	---------------------

THERAPEUTIC INDEX

THERAPEUTIC INDEX

Alimentary tract and metabolism 21

Stomatological preparations 21

Stomatological preparations 21

Drugs for functional gastrointestinal disorders 21

Propulsives 21

Antiemetics and antinauseants 21

Antiemetics and antinauseants 21

Antidiarrheals, intestinal antiinflammatory/ antiinfective agents 22

Intestinal antiinfectives 22

Blood and blood forming organs 23

Blood substitutes and perfusion solutions 23

I.V. solutions 23

Cardiovascular system 24

Cardiac therapy 24

Antiarrhythmics, class I and III 24

Cardiac stimulants excl. cardiac glycosides 24

Vasodilators used in cardiac diseases 24

Dermatologicals 25

Corticosteroids, dermatological preparations 25

Corticosteroids, plain 25

Systemic hormonal preparations, excl. sex hormones and insulins 26

Corticosteroids for systemic use 26

Corticosteroids for systemic use, plain 26

Pancreatic hormones 26

Glycogenolytic hormones 26

Antiinfectives for systemic use 27

Antibacterials for systemic use 27

Tetracyclines 27

Beta-lactam antibacterials, penicillins 27

Other beta-lactam antibacterials 30

Sulfonamides and trimethoprim 32

Macrolides, lincosamides and streptogramins 33

Other antibacterials 34

Musculo-skeletal system 35

Antiinflammatory and antirheumatic products 35

Antiinflammatory and antirheumatic products, non-steroids 35

Nervous system 38

Analgesics 38

Opioids 38

Other analgesics and antipyretics 42

Antiepileptics 43

Antiepileptics 43

THERAPEUTIC INDEX

Anti-Parkinson drugs 43

Anticholinergic agents 43

Psycholeptics 43

Anxiolytics 43

Hypnotics and sedatives 44

Respiratory system 45

Drugs for obstructive airway diseases 45

Adrenergics for systemic use 45

Sensory organs 46

Ophthalmologicals 46

Antiinfectives 46

Various 47

All other therapeutic products 47

All other therapeutic products 47

All other non-therapeutic products 47

All other non-therapeutic products 47

Section 2

Schedule of Benefits

SYMBOLS USED IN THE SCHEDULE

An asterisk (*) against the dispensed price of a benefit indicates that the manufacturer's pack does not coincide with the maximum quantity.

A double dagger (†) in the maximum quantity column indicates an item for which the maximum quantity has been specially determined to correspond to the manufacturer's pack and the manufacturer's standard pack should be prescribed and supplied. For any item where a maximum quantity greater than 1 is marked with a double dagger (†), that maximum quantity should be prescribed and supplied.

A gauge sign (#) against the dispensed price of a benefit indicates that the product is not preconstituted and that an extemporaneously-prepared dispensing fee is included in the dispensed price and, where appropriate, an amount for purified water.

Where a STATE is indicated after a manufacturer's code, that brand may be available only in the State indicated. NSW-(N); Vic-(V); Qld-(Q); SA-(S); WA-(W); Tas-(T).

RESTRICTED BENEFITS

All restricted items have separate headings for authority and non-authority items. In each case these items may be prescribed as pharmaceutical benefits only for use for one of the specified indications. Where more than one indication is specified for an Authority required or Restricted pharmaceutical benefit, each indication is separated from the preceding indication by a semi-colon and commences on the next line. In the case of Authority required (STREAMLINED) items, each indication will also include a four digit streamlined authority code. The drug may be prescribed as a pharmaceutical benefit for a patient who qualifies under any of the specified indications.

A straight line is drawn between entries for different forms and strengths of an item to indicate clearly the different restrictions which apply to these various forms and strengths.

The maximum quantity and/or number of repeats in respect of an item shown in the Schedule may be varied by the Chief Executive Officer of Medicare Australia when approving an Authority Prescription or an Authority to Prescribe. The quantity and number of repeats shown on the authority shall be supplied. (See Explanatory Notes). Payment will be made on the basis of the price shown for that item in the Schedule.

CODES FOR INJECTABLE ITEMS WITH ALLOWABLE SOLVENTS

The entry in this schedule of those pharmaceutical benefit injectable items which require a solvent includes the codes of the items with the relevant solvents. For each such item the code is for the injectable with 10mL sodium chloride injection 9 mg per mL (0.9%).

BRAND EQUIVALENCE

'a' located immediately before brand names of a particular strength of an item indicates that the sponsors of these brands have submitted evidence that they have been demonstrated to be bioequivalent or therapeutically equivalent, or that justification for not needing bioequivalence or therapeutic equivalence data has been provided to and accepted by the Therapeutic Goods Administration. It would thus be expected that these brands may be interchanged without differences in clinical effect.

For other brands of an item, i.e., those not indicated as above, it is unknown whether or not they are equivalent. There may be several reasons for this, such as bioequivalence data not being considered necessary when the products were approved for marketing, or that advice or data have not been forthcoming from sponsors. This does not necessarily suggest a lack of safety or efficacy, but in these circumstances caution should be taken if brands are interchanged.

'b' attached to brand names indicates that these brands are also equivalent, but that it is not known if there is equivalence between brands marked 'a' and brands marked 'b'.

BRAND PREMIUM POLICY

The Brand Premium Policy was introduced on 1 December 1990 to increase price competition by allowing pharmaceutical manufacturers to set their own price on multi-branded items listed on the Pharmaceutical Benefits Scheme and to encourage the development of the generic pharmaceutical industry in Australia. The policy does this by increasing prescribers' and patients' consciousness about the price of drugs. In effect, it makes both groups question whether it is necessary for the patient to pay more for the drugs when a cheaper brand is available. The policy also allows companies to establish prices taking into account competition and consumer acceptance.

The policy operates where there is more than one brand of a particular drug available through the Pharmaceutical Benefits Scheme and where the brands are therapeutically interchangeable. Due to this, the policy mainly applies to out of patent drugs.

Basically the policy operates by:

- the Australian Government subsidising a drug to the level of the lowest priced brand (except in those instances where the lowest priced brand has, as part of its price, a therapeutic group premium);
- suppliers of other brands of that drug being able to set a price above the price charged by the supplier(s) of the lowest priced brand(s); and
- the patient paying the brand premium which is the price difference between the lowest price brand and the brand prescribed.

If a prescription is written generically or for the lowest priced brand, and the lowest priced brand is supplied, there is no brand premium payable.

'B' located immediately before an amount in the premium column indicates a brand premium which applies to that particular brand of the item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

If a brand of a drug which is subject to a special patient contribution also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'S' and 'B' respectively.

THERAPEUTIC GROUP PREMIUM POLICY

The Therapeutic Group Premium Policy was introduced on 1 February 1998 as an extension of the Brand Premium Policy to encourage greater competition between manufacturers of drugs and to make doctors and patients more aware of the costs of medicines.

The Therapeutic Group Premium policy applies within narrowly defined therapeutic sub-groups where the drugs concerned are of similar safety, efficacy and health outcomes.

Basically the policy operates by:

- the Australian Government subsidising drugs within a defined therapeutic sub-group to the level of the lowest priced drug in the sub-group;
- suppliers of other drugs within that sub-group being able to set prices above the price charged by the supplier(s) of the lowest priced drug; and
- the patient paying the therapeutic group premium which is the price difference between the lowest price drug and the drug prescribed.

'T' located immediately before an amount in the premium column indicates a therapeutic group premium which applies to that particular item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

The success of the Government in controlling prices of products supplied through the Pharmaceutical Benefits Scheme has often been criticised by the pharmaceutical industry. Under both the Brand Premium Policy and the Therapeutic Group Premium Policy, suppliers of multi-branded items and therapeutically similar drugs are able to set their own prices at a level that they think the market will bear. At the same time, the prescriber and the patient can decide whether it is necessary to pay more for a particular brand or drug when a cheaper one is available and is therapeutically interchangeable.

The brand premium or therapeutic group premium does not count toward the patient's safety net.

It should be noted that the brand premium or therapeutic group premium is not a Government charge or revenue. The premium arises from the manufacturer's price and the majority goes to the manufacturer with wholesalers and pharmacists receiving a small percentage.

SPECIAL PHARMACEUTICAL BENEFITS

The special patient contribution is payable by all patients in addition to the relevant patient contribution for concessional and general patients.

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Reimburse ment Price for Max. Qty \$	Dispense d Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
PHARMACEUTICAL BENEFITS FOR DENTAL USE								
3310F	AMOXYCILLIN Powder for paediatric oral drops 100 mg per mL, 20 mL	#1	..	\$0.61	#13.18	#13.79	14.59	Amoxil GK

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Alimentary tract and metabolism

Stomatological preparations

Stomatological preparations

Antiinfectives and antiseptics for local oral treatment

AMPHOTERICIN								
3306B	Lozenge 10 mg	20	12.03	13.10	Fungilin	SI
NYSTATIN								
3343Y	Oral suspension 100,000 units per mL, 24 mL	‡1	10.85	11.92	Mycostatin Nilstat	FM SI

Other agents for local oral treatment

BENZYDAMINE HYDROCHLORIDE								
Restricted benefit								
Radiation induced mucositis.								
5032W	Mouth and throat rinse 22.5 mg per 15 mL, 500 mL	‡1	22.26	23.33	Difflam	IA

Drugs for functional gastrointestinal disorders

Propulsives

Propulsives

METOCLOPRAMIDE HYDROCHLORIDE								
5151D	Tablet 10 mg	25	8.20	9.27	Pramin	AF
					^B 3.02	9.27	Maxolon	VT
5153F	Injection 10 mg in 2 mL	10	12.99	14.06	Maxolon	VT

Antiemetics and antinauseants

Antiemetics and antinauseants

Other antiemetics

PROCHLORPERAZINE								
Caution								
Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.								
5205Y	Tablet containing prochlorperazine maleate 5 mg	25	9.51	10.58	^a APO- Prochlorperazine ^a ProCalm ^a Prochlorperazine- GA ^a Stemetil	TX SI GM AV
					^B 3.45	10.58	^a Stemetil	SW
5206B	Injection containing prochlorperazine mesylate 12.5 mg in 1 mL	10	16.82	17.89	Stemetil	SW
5208D	Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5	‡1	19.93	21.00	Stemetil	SW
PROMETHAZINE HYDROCHLORIDE								
3374N	Injection 50 mg in 2 mL	10	*22.32	23.39	Hospira Pty Limited	HH

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Antidiarrheals, intestinal antiinflammatory/ antiinfective agents								

Intestinal antiinfectives
Antibiotics

NYSTATIN

3342X	Tablet 500,000 units	50	17.98	19.05	Nilstat	SI
3345C	Capsule 500,000 units	50	17.98	19.05	Nilstat	SI

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$		Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	--	-----------------------------

Blood and blood forming organs

Blood substitutes and perfusion solutions

I.V. solutions

Solutions for parenteral nutrition

GLUCOSE

5005K	I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL	5	*18.07	19.14	^a	B. Braun Australia Pty Ltd	BR
							^a	Fresenius Kabi Australia Pty Limited	PK
5106R	I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L	5	*23.17	24.24	^a	B. Braun Australia Pty Ltd	BR
							^a	Baxter Healthcare Pty Ltd	BX
							^a	Fresenius Kabi Australia Pty Limited	PK

Solutions affecting the electrolyte balance

SODIUM CHLORIDE

5021G	I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL	5	*18.07	19.14	^a	B. Braun Australia Pty Ltd	BR
							^a	Fresenius Kabi Australia Pty Limited	PK
5212H	I.V. infusion 154 mmol per L (0.9%), 1 L	5	*23.17	24.24	^a	B. Braun Australia Pty Ltd	BR
							^a	Baxter Healthcare Pty Ltd	BX
							^a	Fresenius Kabi Australia Pty Limited	PK
5213J	I.V. infusion 513 mmol per L (3%), 1 L	2	*16.54	17.61		Baxter Healthcare Pty Ltd	BX

SODIUM CHLORIDE with GLUCOSE

5214K	I.V. infusion 31 mmol-222 mmol (anhydrous) per L (0.18%-4%), 1 L	5	*23.52	24.59		Baxter Healthcare Pty Ltd	BX
5215L	I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL (0.225%-3.75%), 500 mL	5	*28.77	29.84		Baxter Healthcare Pty Ltd	BX
5216M	I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL (0.45%-2.5%), 500 mL	5	*28.77	29.84		Baxter Healthcare Pty Ltd	BX

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Cardiovascular system

Cardiac therapy

Antiarrhythmics, class I and III

Antiarrhythmics, class IB

LIGNOCAINE HYDROCHLORIDE

5142P	Injection 100 mg in 5 mL	5	37.33	34.20	Pfizer Australia Pty Ltd	PF
-------	--------------------------	---	----	----	-------	-------	--------------------------	----

Cardiac stimulants excl. cardiac glycosides

Adrenergic and dopaminergic agents

ADRENALINE

5004J	Injection 1 mg in 1 mL (1 in 1,000)	5	20.34	21.41	AstraZeneca Pty Ltd	AP
-------	-------------------------------------	---	----	----	-------	-------	---------------------	----

Vasodilators used in cardiac diseases

Organic nitrates

GLYCERYL TRINITRATE

5108W	Tablets 600 micrograms, 100	1	15.00	16.07	Lycinate	FM
				^B 3.00	18.00	16.07		

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Dermatologicals

Corticosteroids, dermatological preparations

Corticosteroids, plain

Corticosteroids, weak (group I)

HYDROCORTISONE ACETATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

5111B	Cream 10 mg per g (1%), 30 g	‡1	8.94	10.01	^a	Cortic-DS 1%	FM
				^B 2.75	11.69	10.01	^a	Sigmacort	SI
5112C	Topical ointment 10 mg per g (1%), 30 g	‡1	8.94	10.01	^a	Cortic-DS 1%	FM
				^B 2.75	11.69	10.01	^a	Sigmacort	SI
5113D	Cream 10 mg per g (1%), 50 g	‡1	8.61	9.68	^a	Cortic-DS 1%	FM
				^B 0.08	8.69	9.68		Cortef	VT
				^B 2.76	11.37	9.68	^a	Sigmacort	SI
5114E	Topical ointment 10 mg per g (1%), 50 g	‡1	8.61	9.68	^a	Cortic-DS 1%	FM
				^B 2.76	11.37	9.68	^a	Sigmacort	SI

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Systemic hormonal preparations, excl. sex hormones and insulins

Corticosteroids for systemic use

Corticosteroids for systemic use, plain *Glucocorticoids*

BETAMETHASONE ACETATE with BETAMETHASONE SODIUM PHOSPHATE

Restricted benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

5034Y	Injection 3 mg-3.9 mg (equivalent to 5.7 mg betamethasone) in 1 mL	5	25.38	26.45	Celestone Chronodose	SH
-------	--	---	----	----	-------	-------	-------------------------	----

HYDROCORTISONE SODIUM SUCCINATE

Restricted benefit

For use in a hospital.

5118J	Injection equivalent to 100 mg hydrocortisone with 2 mL solvent	6	*37.32	34.20	Solu-Cortef	PF
5119K	Injection equivalent to 250 mg hydrocortisone with 2 mL solvent	6	*59.82	34.20	Solu-Cortef	PF

METHYLPREDNISOLONE ACETATE

Restricted benefit

For local intra-articular or peri-articular infiltration.

5148Y	Injection 40 mg in 1 mL	5	24.60	25.67 ^a	Depo-Nisolone	KR
				^B 0.73	25.33	25.67 ^a	Depo-Medrol	PF

TRIAMCINOLONE ACETONIDE

Restricted benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

5233K	Injection 10 mg in 1 mL	5	25.38	26.45	Kenacort-A10	SI
-------	-------------------------	---	----	----	-------	-------	--------------	----

Pancreatic hormones

Glycogenolytic hormones *Glycogenolytic hormones*

GLUCAGON HYDROCHLORIDE

5105Q	Injection set containing 1 mg (1 i.u.) and 1 mL solvent in disposable syringe	1	45.63	34.20	GlucaGen Hypokit	NO
-------	---	---	----	----	-------	-------	------------------	----

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Antiinfectives for systemic use

Antibacterials for systemic use

Tetracyclines

Tetracyclines

DOXYCYCLINE

Note

Bioequivalence has been demonstrated between doxycycline tablet 100 mg (as hydrochloride) and doxycycline tablet 100 mg (as monohydrate).

3321T	Tablet 100 mg (as hydrochloride)	7	8.47	9.54	^a Doxsig	SI	
							^a Doxy-100	GM	
							^a Doxilin 100	AF	
5082L	Tablet 100 mg (as monohydrate)	7	8.47	9.54	^B 1.19	^a Vibramycin	PF
							^a Chem mart	CH	
							^a Doxycycline		
							^a Doxyhexal	SZ	
							^a GenRx Doxycycline	GX	
							^a Terry White	TW	
							Chemists		
							Doxycycline		

DOXYCYCLINE

3322W	Capsule 100 mg (as hydrochloride)	7	8.47	9.54	^a Mayne Pharma	YT
							Doxycycline	
							^a Doryx	YN

Beta-lactam antibacterials, penicillins

Penicillins with extended spectrum

AMOXYCILLIN

3300Q	Capsule 500 mg	20	10.65	11.72	^a Alphamox 500	AF
							^a Amoxicillin-GA	GM
							^a Amoxicillin	RA
							Ranbaxy	
							^a Amoxicillin Sandoz	SZ
							^a APO-Amoxicillin	TX
							^a Chem mart	CH
							Amoxicillin	
							^a Cilamox	SI
							^a GenRx Amoxicillin	GX
							^a Terry White	TW
							Chemists	
							Amoxicillin	
				^B 0.80	11.45	11.72	^a Amoxil	GK
3301R	Capsule 250 mg	20	8.55	9.62	^a Alphamox 250	AF
							^a Amoxicillin-GA	GM
							^a Amoxicillin	RA
							Ranbaxy	
							^a Amoxicillin Sandoz	SZ
							^a APO-Amoxicillin	TX
							^a Chem mart	CH
							Amoxicillin	
							^a Cilamox	SI
							^a GenRx Amoxicillin	GX
							^a Terry White	TW
							Chemists	
							Amoxicillin	

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 0.79	9.34	9.62	^a Amoxil GK
3302T	Powder for syrup 125 mg per 5 mL, 100 mL	‡1	#10.85	12.26	^a Alphamox 125 AF ^a Amoxicillin Sandoz SZ ^a Bgramin GM ^a Chem mart CH Amoxicillin ^a GenRx Amoxicillin GX ^a Ranmoxy RA ^a Terry White TW Chemists Amoxicillin
3309E	Sachet containing oral powder 3 g	1	9.11	10.18	^a Amoxil GK
3393N	Powder for syrup 250 mg per 5 mL, 100 mL	‡1	#11.69	13.10	^a Alphamox 250 AF ^a Amoxicillin Sandoz SZ ^a Bgramin GM ^a Chem mart CH Amoxicillin ^a Cilamox SI ^a GenRx Amoxicillin GX ^a Ranmoxy RA ^a Terry White TW Chemists Amoxicillin
				^B 0.95	#11.80	12.26	^a Amoxil GK
5225B	Powder for oral suspension 500 mg per 5 mL, 100 mL	‡1	#14.70	16.11	^a Amoxil Forte GK Maxamox SZ
AMPICILLIN							
3313J	Powder for injection 500 mg	5	11.08	12.15	^a Austrapen LN ^a Ibimicyn TS
3314K	Powder for injection 1 g	5	14.07	15.14	^a Aspen Ampicyn AS ^a Austrapen LN ^a Ibimicyn TS
Beta-lactamase sensitive penicillins							
BENZATHINE BENZYL PENICILLIN							
5027N	Injection 900 mg in 2.3 mL single use pre-filled syringe	10	293.11	34.20	Bicillin L-A AS
BENZYL PENICILLIN							
3398W	Powder for injection 600 mg	10	*42.92	34.20	BenPen CS
3399X	Powder for injection 3 g	10	*66.92	34.20	BenPen CS
PHENOXYMETHYL PENICILLIN							
3360W	Tablet 250 mg	50	*11.58	12.65	Abbecillin-VK Filmtab SI
3361X	Tablet 500 mg	50	*14.06	15.13	Abbecillin-VK Filmtab SI
3363B	Capsule 250 mg	50	11.41	12.48	^a Cilicaine VK FM ^a Cilopen VK GM LPV AS
3364C	Capsule 500 mg	50	13.84	14.91	^a Cilicaine VK FM ^a Cilopen VK GM LPV AS
5012T	Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL	2	*22.40	23.47	^a Cilicaine V FM

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium B	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				2.00	*24.40	23.47 ^a	Abbecillin-V SI

3371K	PROCAINE PENICILLIN Injection 1.5 g	5	92.22	34.20	Cilicaïne SI
-------	---	---	----	----	-------	-------	--------------

Beta-lactamase resistant penicillins

DICLOXACILLIN

Restricted benefit

Serious staphylococcal infections.

5096F	Capsule 250 mg	24	11.45	12.52 ^a	Dicloxig SI
						^a	Distaph 250 AF
5097G	Capsule 500 mg	24	16.94	18.01 ^a	Diclocil BQ
						^a	Dicloxig SI
						^a	Distaph 500 AF

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

5094D	Powder for injection 500 mg	5	15.49	16.56 ^a	Flubiclox TS
						^a	Flucil AS
5095E	Powder for injection 1 g	5	20.66	21.73 ^a	Flubiclox TS
						^a	Flucil AS
						^a	Hospira Pty Limited HH

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

Restricted benefit

Serious staphylococcal infections.

5090X	Capsule 250 mg (as sodium)	24	11.45	12.52 ^a	Flophen AS
						^a	Staphylex 250 AF
5091Y	Capsule 500 mg (as sodium)	24	16.94	18.01 ^a	Flophen AS
						^a	Staphylex 500 AF
5257Q	Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL	¥1	#16.37	17.78	Aspen Pharmacare Australia Pty Limited LN
5258R	Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL	¥1	#20.08	21.49	Aspen Pharmacare Australia Pty Limited LN

Combinations of penicillins, incl. beta-lactamase inhibitors

AMOXYCILLIN with CLAVULANIC ACID

Caution

Hepatotoxicity has been reported with this drug.

Restricted benefit

Infections where resistance to amoxicillin is suspected;

Infections where resistance to amoxicillin is proven.

5006L	Tablet 875 mg-125 mg	10	14.60	15.67 ^a	Amoxicillin/ Clavulanic Acid 875/125 generichealth GQ
						^a	Chem mart CH
							Amoxicillin and Clavulanic Acid

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Clamoxyl Duo forte AL
							^a Clavycillin 875/125 CR
							^a Curam Duo Forte SZ
							^a GA-Amclav Forte GM
							^a 875/125
							^a GenRx Amoxicillin and Clavulanic Acid GX
							^a Moxiclav Duo Forte SI
							^a 875/125
							^a Terry White Chemists TW
							^a Amoxicillin and Clavulanic Acid
				^B 2.04	16.64	15.67	^a Augmentin Duo forte GK
5008N	Tablet 500 mg-125 mg	10	12.16	13.23	^a Amoxicillin/ Clavulanic Acid 500/125 generichealth GQ
							^a APO-Amoxicillin/ Clavulanic Acid 500/125 TX
							^a Clamoxyl Duo AL
							^a Curam Duo SZ
							^a 500/125
							^a GA-Amclav GM
							^a 500/125
							^a Moxiclav Duo SI
							^a 500/125
				^B 1.55	13.71	13.23	^a Augmentin Duo GK
5009P	Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL	‡1	#12.48	13.89	^a Clamoxyl AL
							^a Curam SZ
							^a Augmentin GK
				^B 1.51	#13.99	13.89	^a Clamoxyl Duo 400 AL
5011R	Powder for syrup 400 mg-57 mg per 5 mL, 60 mL	‡1	#13.99	15.40	^a Curam Duo SZ
							^a Augmentin Duo GK
							^a 400

TICARCILLIN with CLAVULANIC ACID**Restricted benefit**

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.

5230G	Powder for injection 3 g-100 mg (solvent required) (code 7043Q applies to above item with approved solvent)	10	163.32	34.20	Timentin GK
-------	--	----	----	----	--------	-------	-------------

Other beta-lactam antibacterials
First-generation cephalosporins

CEFALOTIN

3376Q	Powder for injection 1 g	10	26.25	27.32	^a Cefalotin Sandoz SZ
							^a Hospira Pty Limited HH
							^a Keflin Neutral AS

CEPHALEXIN

3317N	Capsule 250 mg	20	8.85	9.92	^a Cefalexin Sandoz SZ
							^a Cephabell BF
							^a Cephalixin generichealth GQ
							^a Cephatrust 250 MI

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Chem mart Cephalexin CH
							^a Cilex GM
							^a GenRx Cephalexin GX
							^a Ialex LN
							^a Ibilex 250 AF
							^a Rancef RA
							^a Terry White Chemists Cephalexin TW
				^B 3.30	12.15	9.92	^a Keflex AS
3318P	Capsule 500 mg	20	10.77	11.84	^a Cefalexin Sandoz SZ
							^a Cephabell BF
							^a Cephalexin generichealth GQ
							^a Cephatrust 500 MI
							^a Chem mart Cephalexin CH
							^a Cilex GM
							^a GenRx Cephalexin GX
							^a Ialex LN
							^a Ibilex 500 AF
							^a Rancef RA
							^a Terry White Chemists Cephalexin TW
				^B 4.41	15.18	11.84	^a Keflex AS
3319Q	Granules for syrup 125 mg per 5 mL, 100 mL	‡1	#11.84	13.25	^a APO-Cephalexin TX
							^a Cefalexin Sandoz SZ
							^a Chem mart Cephalexin CH
							^a Cilex GM
							^a GenRx Cephalexin GX
							^a Ialex LN
							^a Ibilex 125 AF
							^a Terry White Chemists Cephalexin TW
				^B 3.55	#15.39	13.25	^a Keflex AS
3320R	Granules for syrup 250 mg per 5 mL, 100 mL	‡1	#13.24	14.65	^a APO-Cephalexin TX
							^a Cefalexin Sandoz SZ
							^a Chem mart Cephalexin CH
							^a Cilex GM
							^a GenRx Cephalexin GX
							^a Ialex LN
							^a Ibilex 250 AF
							^a Terry White Chemists Cephalexin TW
				^B 4.38	#17.62	14.65	^a Keflex AS

Second-generation cephalosporins

CEFACTOR

Caution

Serum sickness-like reactions have been reported with this drug, especially in children.

5045M	Tablet 375 mg (sustained release)	10	12.89	13.96	^a Cefaclor-GA GN
							^a Chem mart Cefaclor CD CH

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
							^a Douglas Cefaclor- CD GM
							^a GenRx Cefaclor CD GX
							^a Karlor CD LN
							^a Keflor CD AF
							^a Ozcef RA
							^a Terry White Chemists Cefaclor CD TW
				^B 5.20	18.09	13.96	^a Ceclor CD AS
5046N	Powder for oral suspension 125 mg per 5 mL, 100 mL	#1	#13.50	14.91	^a Aclor 125 SI
							^a Cefaclor Sandoz SZ
							^a Chem mart Cefaclor CH
							^a GenRx Cefaclor GX
							^a Keflor AF
							^a Ozcef RA
							^a Terry White Chemists Cefaclor TW
				^B 4.18	#17.68	14.91	^a Ceclor AS
5047P	Powder for oral suspension 250 mg per 5 mL, 75 mL	#1	#13.83	15.24	^a Aclor 250 SI
							^a Cefaclor Sandoz SZ
							^a Chem mart Cefaclor CH
							^a GenRx Cefaclor GX
							^a Keflor AF
							^a Ozcef RA
							^a Terry White Chemists Cefaclor TW
				^B 4.37	#18.20	15.24	^a Ceclor AS
	CEFUROXIME AXETIL						
5052X	Tablet 250 mg (base)	14	18.62	19.69	Zinnat GK

Third-generation cephalosporins

CEFOTAXIME

Restricted benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.

5048Q	Powder for injection 1 g	10	*26.82 26.86	27.89 27.93	^a Cefotaxime Sandoz SZ ^a Hospira Pty Limited HH
5049R	Powder for injection 2 g	10	*43.62 43.68	34.20 34.20	^a Cefotaxime Sandoz SZ ^a Hospira Pty Limited HH

Sulfonamides and trimethoprim

Combinations of sulfonamides and trimethoprim, incl. derivatives

TRIMETHOPRIM with SULFAMETHOXAZOLE

Caution

There is an increased risk of severe adverse reactions with this combination in the elderly.

3389J	Tablet 80 mg-400 mg	10	8.67	9.74	Resprim AF
3390K	Tablet 160 mg-800 mg	10	9.39	10.46	^a Bactrim DS RO ^a Resprim Forte AF
				^B 1.54	10.93	10.46	^a Septrin Forte SI
3391L	Oral suspension 40 mg-200 mg per 5 mL, 100 mL	#1	9.05	10.12	Bactrim RO

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
				^B 1.90	10.95	10.12	Septrin SI

Macrolides, lincosamides and streptogramins

Macrolides

ERYTHROMYCIN							
3325B	Capsule 250 mg	25	9.43	10.50	^a Mayne Pharma Erythromycin YT
				^B 1.35	10.78	10.50	^a Eryc YN
ERYTHROMYCIN ETHYL SUCCINATE							
3334L	Powder for oral liquid 200 mg (base) per 5 mL, 100 mL	‡1	#12.32	13.73	^a E-Mycin 200 AF
				^B 2.86	#15.18	13.73	^a E.E.S. 200 LM
3336N	Tablet 400 mg (base)	25	10.92	11.99	^a E-Mycin AF
				^B 2.80	13.72	11.99	^a E.E.S. 400 Filmtab LM
3337P	Powder for oral liquid 400 mg (base) per 5 mL, 100 mL	‡1	#13.40	14.81	^a E-Mycin 400 AF
				^B 2.89	#16.29	14.81	^a E.E.S. Granules LM
ERYTHROMYCIN LACTOBIONATE							
5088T	Powder for I.V. infusion 1 g (base)	5	*88.92	34.20	Erythrocin-I.V. LM
ROXITHROMYCIN							
5259T	Tablet for oral suspension 50 mg	10	12.89	13.96	Rulide D SW
5260W	Tablet 150 mg	10	11.76	12.83	^a APO-Roxithromycin TX ^a Biaxsig AV ^a Chem mart Roxithromycin CH ^a Roxar 150 SI ^a Roxide SZ ^a Roximycin AF ^a Roxithromycin-GA GM ^a Terry White Chemists Roxithromycin TW
				^B 2.60	14.36	12.83	^a Rulide SW
5261X	Tablet 300 mg	5	11.76	12.83	^a APO-Roxithromycin TX ^a Biaxsig AV ^a Chem mart Roxithromycin CH ^a Roxar 300 SI ^a Roxide SZ ^a Roximycin AF ^a Roxithromycin-GA GM ^a Terry White Chemists Roxithromycin TW
				^B 2.60	14.36	12.83	^a Rulide SW

Lincosamides

CLINDAMYCIN

Restricted benefit

Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin.

5057E	Capsule 150 mg	24	20.02	21.09	^a Cleocin KR
				^B 1.40	21.42	21.09	^a Dalacin C PF

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
5144R	LINCOMYCIN Injection 600 mg in 2 mL	5	33.74	34.20	Lincocin PF

Other antibacterials

Glycopeptide antibacterials

VANCOMYCIN

Restricted benefit

Prophylaxis of endocarditis in patients hypersensitive to penicillin.

3323X	Powder for injection 500 mg (500,000 i.u.) vancomycin activity	2	*17.96	19.03	^a Hospira Pty Limited HH
							^a Vancocin CP AS
							^a Vancomycin Sandoz SZ
5083M	Powder for injection 1 g (1,000,000 i.u.) vancomycin activity	1	17.95	19.02	^a Hospira Pty Limited HH
							^a Vancomycin Sandoz SZ

Imidazole derivatives

METRONIDAZOLE

3339R	Tablet 200 mg	21	7.96	9.03	^a Metrogyl 200 AF
							^a Metronide 200 AV
				^B 2.30	10.26	9.03	^a Flagyl SW
5157K	Suppositories 500 mg, 10	‡1	23.16	24.23	Flagyl SW
5159M	Tablet 400 mg	5	7.88	8.95	Metrogyl 400 AF

METRONIDAZOLE

Restricted benefit

Treatment of anaerobic infections.

5155H	Tablet 400 mg	21	10.03	11.10	^a Metrogyl 400 AF
							^a Metronide 400 AV
				^B 2.30	12.33	11.10	^a Flagyl SW

METRONIDAZOLE

Restricted benefit

Treatment, in a hospital, of acute anaerobic sepsis.

5154G	I.V. infusion 500 mg in 100 mL	5	*31.97	33.04	^a Baxter Healthcare Pty Ltd BX
					*32.00	33.07	^a DBL Metronidazole Intravenous Infusion HH
							^a Metronidazole Sandoz SZ

METRONIDAZOLE BENZOATE

3341W	Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL	‡1	18.82	19.89	Flagyl S SW
-------	--	----	----	----	-------	-------	-------------

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Musculo-skeletal system

Antiinflammatory and antirheumatic products

Antiinflammatory and antirheumatic products, non-steroids *Acetic acid derivatives and related substances*

5079H	DICLOFENAC SODIUM Suppository 100 mg	40	*24.92	25.99	Voltaren 100	NV
<hr/>								
DICLOFENAC SODIUM								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component; Bone pain due to malignant disease.								
5076E	Tablet 25 mg (enteric coated)	100	*13.06	14.13	^a APO-Diclofenac ^a Chem mart Diclofenac ^a Clonac 25 ^a Diclofenac-GA ^a Diclofenac Sandoz ^a Fenac 25 ^a Terry White Chemists Diclofenac	TX CH SI GM SZ AF TW
5077F	Tablet 50 mg (enteric coated)	50	^B 1.96 *15.02 11.05	14.13 12.12	^a Voltaren 25 ^a APO-Diclofenac ^a Chem mart Diclofenac ^a Clonac 50 ^a Diclofenac-GA ^a Diclofenac Sandoz ^a Fenac ^a Terry White Chemists Diclofenac	NV TX CH SI GM SZ AF TW
5077F				^B 1.96	13.01	12.12	^a Voltaren 50	NV
<hr/>								
5128X	INDOMETHACIN Suppository 100 mg	40	*22.50	23.57	Indocid	AS
<hr/>								
INDOMETHACIN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component; Bone pain due to malignant disease.								
5126T	Capsule 25 mg	100	*12.08 ^B 2.16 *14.24	13.15 13.15	^a Arthrexin ^a Indocid	AF AS
<hr/>								
SULINDAC								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component; Bone pain due to malignant disease.								
5217N	Tablet 100 mg	100	*16.34	17.41	Aclin	AF
5218P	Tablet 200 mg	50	15.28	16.35	Aclin 200	AF

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
Oxicams								
PIROXICAM								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component.								
5201R	Dispersible tablet 10 mg	50	12.50	13.57	Mobilis D-10	AF
5202T	Dispersible tablet 20 mg	25	12.20	13.27	^a Mobilis D-20	AF
				^B 2.64	14.84	13.27	^a Feldene-D	PF
5203W	Capsule 10 mg	50	12.50	13.57	^a Chem mart	CH
							^a Piroxicam	
							^a GenRx Piroxicam	GX
							^a Mobilis 10	AF
							^a Terry White	TW
							Chemists	
							Piroxicam	
				^B 2.66	15.16	13.57	^a Feldene	PF
5204X	Capsule 20 mg	25	12.20	13.27	^a Chem mart	CH
							^a Piroxicam	
							^a GenRx Piroxicam	GX
							^a Mobilis 20	AF
							^a Terry White	TW
							Chemists	
							Piroxicam	
				^B 2.64	14.84	13.27	^a Feldene	PF
Propionic acid derivatives								
IBUPROFEN								
5124Q	Tablet 400 mg	30	9.19	10.26	Brufen	AB
<hr/>								
IBUPROFEN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component;								
Bone pain due to malignant disease.								
5123P	Tablet 400 mg	90	*14.73	15.80	Brufen	AB
<hr/>								
KETOPROFEN								
5139L	Suppository 100 mg	40	*25.30	26.37	Orudis	SW
<hr/>								
KETOPROFEN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component.								
5136H	Capsule 200 mg (sustained release)	28	19.37	20.44	^a Oruvail SR	AV
				^B 2.21	21.58	20.44	^a Orudis SR 200	SW
<hr/>								
NAPROXEN								
<u>Restricted benefit</u>								
Chronic arthropathies (including osteoarthritis) with an inflammatory component;								
Bone pain due to malignant disease.								
5176K	Tablet 250 mg	100	*13.72	14.79	^a Inza 250	AF
				^B 2.34	*16.06	14.79	^a Naprosyn	RO
5177L	Tablet 500 mg	50	12.91	13.98	^a Inza 500	AF
				^B 1.36	14.27	13.98	^a Naprosyn	RO
5178M	Tablet 750 mg (sustained release)	28	12.38	13.45	^a Proxen SR 750	MD
				^B 1.27	13.65	13.45	^a Naprosyn SR750	RO

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
5179N	Tablet 1 g (sustained release)	28	14.37	15.44 ^a	Proxen SR 1000 MD
				^B 1.34	15.71	15.44 ^a	Naprosyn SR1000 RO

NAPROXEN SODIUM**Restricted benefit**

Chronic arthropathies (including osteoarthritis) with an inflammatory component;

Bone pain due to malignant disease.

Note

Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.

5186Y	Tablet 550 mg	50	13.10	14.17 ^a	Crysanal MD
				^B 2.29	15.39	14.17 ^a	Anaprox 550 RO

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer
------	---	-------------	-------------	---------	--	--	-----------------------------

Nervous system

Analgesics

Opioids

Natural opium alkaloids

CODEINE PHOSPHATE

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5063L	Tablet 30 mg	20	16.87	17.94	Fawns and McAllan Proprietary Limited	FM
-------	--------------	----	----	----	-------	-------	---	----

CODEINE PHOSPHATE with PARACETAMOL

3316M	Tablet 30 mg-500 mg	20	8.08	9.15	^a APO- Paracetamol/Co deine 500/30	TX
							^a Codalgin Forte	FM
							^a Codapane Forte	AL
							^a Comfarol Forte	SZ
							^a Dolaforte	CO
							^a Prodeine Forte	AV
				^B 2.80	10.88	9.15	^a Panadeine Forte	SW

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5129Y	Injection 2 mg in 1 mL	5	22.84	23.91	Dilaudid	MF
5130B	Injection 10 mg in 1 mL	5	28.97	30.04	Dilaudid-HP	MF
5131C	Injection 50 mg in 5 mL	5	52.00	34.20	Dilaudid-HP	MF

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5115F	Tablet 2 mg	20	17.10	18.17	Dilaudid	MF
5116G	Tablet 4 mg	20	19.85	20.92	Dilaudid	MF
5117H	Tablet 8 mg	20	30.03	31.10	Dilaudid	MF
5132D	Oral liquid 1 mg per mL, 473 mL	1	63.70	34.20	Dilaudid	MF

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
3357Q	Tablet 8 mg (modified release)	14	36.41	34.20	Jurnista	JC
3358R	Tablet 16 mg (modified release)	14	52.82	34.20	Jurnista	JC
3367F	Tablet 32 mg (modified release)	14	88.70	34.20	Jurnista	JC
3368G	Tablet 64 mg (modified release)	14	149.38	34.20	Jurnista	JC
5023J	Tablet 4 mg (modified release)	14	30.95	32.02	Jurnista	JC

MORPHINE HYDROCHLORIDE**Caution**

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5237P	Oral solution 2 mg per mL, 200 mL	1	18.16	19.23	Ordine 2	MF
5238Q	Oral solution 5 mg per mL, 200 mL	1	20.78	21.85	Ordine 5	MF
5239R	Oral solution 10 mg per mL, 200 mL	1	24.92	25.99	Ordine 10	MF

MORPHINE SULFATE**Caution**

The risk of drug dependence is high.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5168B	Injection 10 mg in 1 mL	5	14.10	15.17	Hospira Pty Limited	HH
5169C	Injection 15 mg in 1 mL	5	14.45	15.52	Hospira Pty Limited	HH
5170D	Injection 30 mg in 1 mL	5	15.90	16.97	Hospira Pty Limited	HH

MORPHINE SULFATE**Caution**

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5163R	Tablet 30 mg	20	14.13	15.20	Anamorph	FM
-------	--------------	----	----	----	-------	-------	----------	----

MORPHINE SULFATE**Caution**

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5064M	Capsule 30 mg (controlled release)	10	20.12	21.19	MS Mono	MF
5065N	Capsule 60 mg (controlled release)	10	28.62	29.69	MS Mono	MF
5066P	Capsule 90 mg (controlled release)	10	32.67	33.74	MS Mono	MF
5067Q	Capsule 120 mg (controlled release)	10	43.37	34.20	MS Mono	MF
5161P	Tablet 15 mg (controlled release)	20	20.12	21.19	MS Contin	MF
5162Q	Tablet 5 mg (controlled release)	20	15.29	16.36	MS Contin	MF
5164T	Tablet 10 mg (controlled release)	20	17.08	18.15	^a Momex SR 10	SI
							^a MS Contin	MF
5165W	Tablet 30 mg (controlled release)	20	28.62	29.69	^a Momex SR 30	SI

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
5166X	Tablet 60 mg (controlled release)	20	43.37	34.20	^a MS Contin ^a Momex SR 60 ^a MS Contin ^a Momex SR 100 ^a MS Contin	MF SI MF
5167Y	Tablet 100 mg (controlled release)	20	55.63	34.20	MS Contin	MF
5171E	Sachet containing controlled release granules for oral suspension, 20 mg per sachet	20	47.53	34.20	MS Contin Suspension 20 mg	MF
5240T	Capsule 20 mg (containing sustained release pellets)	20	20.70	21.77	Kapanol	GK
5241W	Capsule 50 mg (containing sustained release pellets)	20	34.04	34.20	Kapanol	GK
5242X	Capsule 100 mg (containing sustained release pellets)	20	54.27	34.20	Kapanol	GK
5243Y	Sachet containing controlled release granules for oral suspension, 30 mg per sachet	20	48.71	34.20	MS Contin Suspension 30 mg	MF
5244B	Sachet containing controlled release granules for oral suspension, 60 mg per sachet	20	53.87	34.20	MS Contin Suspension 60 mg	MF
5245C	Sachet containing controlled release granules for oral suspension, 100 mg per sachet	20	65.42	34.20	MS Contin Suspension 100 mg	MF
5246D	Capsule 10 mg (containing sustained release pellets)	20	17.08	18.15	Kapanol	GK

OXYCODONE**Caution**

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5194J	Suppository 30 mg	12	43.66	34.20	Proladone	PL
-------	-------------------	----	----	----	-------	-------	-----------	----

OXYCODONE HYDROCHLORIDE**Caution**

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5190E	Oral solution 5 mg per 5 mL, 250 mL	1	20.72	21.79	OxyNorm Liquid 5mg/5mL	MF
5191F	Capsule 5 mg	20	12.30	13.37	OxyNorm	MF
5195K	Tablet 5 mg	20	12.30	13.37	Endone	SI
5197M	Capsule 10 mg	20	15.42	16.49	OxyNorm	MF
5198N	Capsule 20 mg	20	20.15	21.22	OxyNorm	MF

OXYCODONE HYDROCHLORIDE**Caution**

The risk of drug dependence is high.

Restricted benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

5015Y	Tablet 15 mg (controlled release)	20	27.93	29.00	OxyContin	MF
5016B	Tablet 30 mg (controlled release)	20	41.22	34.20	OxyContin	MF

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer	
					for Max. Qty \$	Recordable Value for Safety Net \$		
5227D	Tablet 5 mg (controlled release)	20	21.18	22.25	OxyContin	MF
5247E	Tablet 10 mg (controlled release)	20	21.95	23.02	OxyContin	MF
5248F	Tablet 20 mg (controlled release)	20	31.87	32.94	OxyContin	MF
5249G	Tablet 40 mg (controlled release)	20	48.35	34.20	OxyContin	MF
5250H	Tablet 80 mg (controlled release)	20	71.70	34.20	OxyContin	MF

Other opioids

TRAMADOL HYDROCHLORIDE

Restricted benefit

For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed;

For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed.

5232J	Capsule 50 mg	20	9.16	10.23	^a APO-Tramadol	TX
							^a Chem mart	CH
							Tramadol	
							^a GA Tramadol 50mg	GM
							^a GenRx Tramadol	GX
							^a Lodam 50	ZP
							^a Terry White	TW
							Chemists	
							Tramadol	
^a Tramadol Sandoz	SZ							
^a Tramedo	AF							
^a Zydol	SI							
			^B 2.42	11.58	10.23	^a Tramal	CS	

TRAMADOL HYDROCHLORIDE

Restricted benefit

For pain where aspirin and/or paracetamol alone are inappropriate or have failed.

3338Q	Tablet 50 mg (twice daily sustained release)	20	11.63	12.70	Tramal SR 50	CS
5001F	Tablet 100 mg (once a day extended release)	10	13.37	14.44	Durotram XR	IA
5002G	Tablet 200 mg (once a day extended release)	10	16.34	17.41	Durotram XR	IA
5003H	Tablet 300 mg (once a day extended release)	10	19.79	20.86	Durotram XR	IA
5150C	Oral drops 100 mg per mL, 10 mL	≠1	13.71	14.78	Tramal	CS
5234L	Tablet 100 mg (twice daily sustained release)	20	13.86	14.93	^a APO-Tramadol SR	TX
							^a Chem mart	CH
							Tramadol SR	
							^a GA Tramadol SR	GM
							100mg	
							^a Lodam SR 100	ZP
							^a Terry White	TW
							Chemists	
							Tramadol SR	
^a Tramahexal SR	SZ							
^a Tramedo SR 100	AF							
^a Zydol SR 100	SI							
			^B 4.51	18.37	14.93	^a Tramal SR 100	CS	
5235M	Tablet 150 mg (twice daily sustained release)	20	16.45	17.52	^a APO-Tramadol SR	TX
							^a Chem mart	CH
							Tramadol SR	
							^a GA Tramadol SR	GM
							150mg	
							^a Lodam SR 150	ZP
^a Terry White	TW							
Chemists								
Tramadol SR								
^a Tramadol Sandoz	SZ							
SR								

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer			
5236N	Tablet 200 mg (twice daily sustained release)	20	18.63	19.70	^a Tramedo SR 150 AF			
							^a Zydol SR 150 SI			
							^B 5.37	21.82	17.52	^a Tramal SR 150 CS
							^a APO-Tramadol SR TX			
							^a Chem mart CH			
							^a Tramadol SR			
							^a GA Tramadol SR GM			
							^a 200mg			
							^a Lodam SR 200 ZP			
							^a Terry White TW			
							^a Chemists			
							^a Tramadol SR			
^a Tramahexal SR SZ										
^a Tramedo SR 200 AF										
^a Zydol SR 200 SI										
^B 6.09	24.72	19.70	^a Tramal SR 200 CS							

TRAMADOL HYDROCHLORIDE**Restricted benefit**

Short-term treatment of acute pain.

5231H	Injection 100 mg in 2 mL	5	14.30	15.37	^a Tramahexal SZ
							^a Tramal 100 CS

Other analgesics and antipyretics
Salicylic acid and derivatives

ASPIRIN

5018D	Tablet 300 mg (dispersible)	96	8.55	9.62	Solprin RC
-------	-----------------------------	----	----	----	------	------	------------

Anilides**PARACETAMOL**

3348F	Oral liquid 120 mg per 5 mL, 100 mL	‡1	9.38	10.45	Panamax SW
3349G	Oral liquid 240 mg per 5 mL, 200 mL	‡1	10.68	11.75	Panamax 240 Elixir SW
5196L	Tablet 500 mg	100	8.42	9.49	^a APO-Paracetamol TX
							^a Chem mart CH
							^a Paracetamol
							^a Febridol GM
							^a Generic Health Pty GQ
							^a Ltd
							^a Panamax SW
							^a Paracetamol SZ
							^a Sandoz
							^a Paralgin FM
^a Pharmacy Choice YM							
^a Paracetamol							
^a Terry White TW							
^a Chemists							
^a Paracetamol							

PARACETAMOL**Restricted benefit**

Chronic arthropathies.

5224Y	Tablet 500 mg	300	*12.42	13.49	^a APO-Paracetamol TX
							^a Chem mart CH
							^a Paracetamol
^a Febridol GM							

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
				^B 2.75	10.42	8.74 ^a	Murelax Serepax	FM SI

Hypnotics and sedatives
Benzodiazepine derivatives

	NITRAZEPAM							
5189D	Tablet 5 mg	25	7.89	8.96 ^a	Alodorm	AF
				^B 1.53	9.42	8.96 ^a	Mogadon	VT
	TEMAZEPAM							
5221T	Tablet 10 mg	25	7.71	8.78 ^a	APO-Temazepam	TX
							Temaze	AF
							Temtabs	FM
				^B 1.50	9.21	8.78 ^a	Normison	SI

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Respiratory system

Drugs for obstructive airway diseases

Adrenergics for systemic use

Alpha- and beta-adrenoceptor agonists

5004J	ADRENALINE Injection 1 mg in 1 mL (1 in 1,000)	5	20.34	21.41	AstraZeneca Pty Ltd	AP
-------	--	---	----	----	-------	-------	------------------------	----

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Sensory organs

Ophthalmologicals

Antiinfectives

Antibiotics

CHLORAMPHENICOL								
5055C	Eye drops 5 mg per mL (0.5%), 10 mL	‡1	11.00	12.07	Chloromycetin Chlorsig	PF SI

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price for Max. Qty \$	Maximum Recordable Value for Safety Net \$	Brand Name and Manufacturer	
------	---	-------------	-------------	---------	--	--	-----------------------------	--

Various

All other therapeutic products

All other therapeutic products

Antidotes

5175J	NALOXONE HYDROCHLORIDE Injection 2 mg in 5 mL	1	43.49	34.20	Naloxone Min-I-Jet	CS
-------	---	---	----	----	-------	-------	--------------------	----

All other non-therapeutic products

All other non-therapeutic products

Solvents and diluting agents, incl. irrigating solutions

5211G	SODIUM CHLORIDE Injection 9 mg per mL (0.9%), 10 mL	5	16.48	17.55	Pfizer Australia Pty Ltd	PF
-------	---	---	----	----	-------	-------	-----------------------------	----

GENERIC/PROPRIETARY INDEX

GENERIC/PROPEIETARY INDEX

A

<i>Abbacillin-V (SI)</i>	29
<i>Abbacillin-VK Filmtab (SI)</i>	28
<i>Aclin (AF)</i>	35
<i>Aclin 200 (AF)</i>	35
<i>Aclor 125 (SI)</i>	32
<i>Aclor 250 (SI)</i>	32
<i>ADRENALINE</i>	24, 45
<i>Alepam 15 (AF)</i>	43
<i>Alepam 30 (AF)</i>	43
<i>Alodorm (AF)</i>	44
<i>Alphamox 125 (AF)</i>	28
<i>Alphamox 250 (AF)</i>	27, 28
<i>Alphamox 500 (AF)</i>	27
<i>Amoxil (GK)</i>	20, 27, 28
<i>Amoxil Forte (GK)</i>	28
<i>AMOXYCILLIN</i>	20, 27
<i>Amoxycillin Ranbaxy (RA)</i>	27
<i>Amoxycillin Sandoz (SZ)</i>	27, 28
<i>AMOXYCILLIN with CLAVULANIC ACID</i>	29
<i>Amoxycillin/ Clavulanic Acid 500/125 generichealth (GQ)</i>	30
<i>Amoxycillin/ Clavulanic Acid 875/125 generichealth (GQ)</i>	29
<i>Amoxycillin-GA (GM)</i>	27
<i>AMPHOTERICIN</i>	21
<i>AMPICILLIN</i>	28
<i>Anamorph (FM)</i>	39
<i>Anaprox 550 (RO)</i>	37
<i>Anginine Stabilised (SI)</i>	24
<i>Antenex 2 (AF)</i>	43
<i>Antenex 5 (AF)</i>	43
<i>APO- Paracetamol/Codeine 500/30 (TX)</i>	38
<i>APO-Amoxycillin (TX)</i>	27
<i>APO-Amoxycillin/ Clavulanic Acid 500/125 (TX)</i>	30
<i>APO-Cephalexin (TX)</i>	31
<i>APO-Diclofenac (TX)</i>	35
<i>APO-Oxazepam (TX)</i>	43
<i>APO-Paracetamol (TX)</i>	42
<i>APO-Prochlorperazine (TX)</i>	21
<i>APO-Roxithromycin (TX)</i>	33
<i>APO-Temazepam (TX)</i>	44
<i>APO-Tramadol (TX)</i>	41
<i>APO-Tramadol SR (TX)</i>	41, 42
<i>Arthrexin (AF)</i>	35
<i>Aspen Ampicyn (AS)</i>	28
<i>Aspen Pharmacare Australia Pty Limited (LN)</i>	29
<i>ASPIRIN</i>	42
<i>AstraZeneca Pty Ltd (AP)</i>	24, 45
<i>Augmentin (GK)</i>	30
<i>Augmentin Duo (GK)</i>	30
<i>Augmentin Duo 400 (GK)</i>	30
<i>Augmentin Duo forte (GK)</i>	30
<i>Austrapen (LN)</i>	28

B

<i>B. Braun Australia Pty Ltd (BR)</i>	23
<i>Bactrim (RO)</i>	32

<i>Bactrim DS (RO)</i>	32
<i>Baxter Healthcare Pty Ltd (BX)</i>	23, 34
<i>BenPen (CS)</i>	28
<i>BENZATHINE BENZYL PENICILLIN</i>	28
<i>BENZTROPINE MESYLATE</i>	43
<i>BENZYDAMINE HYDROCHLORIDE</i>	21
<i>BENZYL PENICILLIN</i>	28
<i>BETAMETHASONE ACETATE with BETAMETHASONE</i> <i>SODIUM PHOSPHATE</i>	26
<i>Bgramin (GM)</i>	28
<i>Biaxig (AV)</i>	33
<i>Bicillin L-A (AS)</i>	28
<i>Brufen (AB)</i>	36

C

<i>CARBAMAZEPINE</i>	43
<i>Carbamazepine Sandoz (SZ)</i>	43
<i>Ceclor (AS)</i>	32
<i>Ceclor CD (AS)</i>	32
<i>CEFACTOR</i>	31
<i>Cefaclor Sandoz (SZ)</i>	32
<i>Cefaclor-GA (GN)</i>	31
<i>Cefalexin Sandoz (SZ)</i>	30, 31
<i>CEFALOTIN</i>	30
<i>Cefalotin Sandoz (SZ)</i>	30
<i>CEFOTAXIME</i>	32
<i>Cefotaxime Sandoz (SZ)</i>	32
<i>CEFUROXIME AXETIL</i>	32
<i>Celestone Chronodose (SH)</i>	26
<i>Cephabeil (BF)</i>	30, 31
<i>CEPHALEXIN</i>	30
<i>Cephalexin generichealth (GQ)</i>	30, 31
<i>Cephatrust 250 (MI)</i>	30
<i>Cephatrust 500 (MI)</i>	31
<i>Chem mart Amoxycillin (CH)</i>	27, 28
<i>Chem mart Amoxycillin and Clavulanic Acid (CH)</i>	29
<i>Chem mart Cefaclor (CH)</i>	32
<i>Chem mart Cefaclor CD (CH)</i>	31
<i>Chem mart Cephalexin (CH)</i>	31
<i>Chem mart Diclofenac (CH)</i>	35
<i>Chem mart Doxycycline (CH)</i>	27
<i>Chem mart Paracetamol (CH)</i>	42
<i>Chem mart Piroxicam (CH)</i>	36
<i>Chem mart Roxithromycin (CH)</i>	33
<i>Chem mart Tramadol (CH)</i>	41
<i>Chem mart Tramadol SR (CH)</i>	41, 42
<i>CHLORAMPHENICOL</i>	46
<i>Chloromycetin (PF)</i>	46
<i>Chlorsig (SI)</i>	46
<i>Cilamox (SI)</i>	27, 28
<i>Cilex (GM)</i>	31
<i>Cilicaine (SI)</i>	29
<i>Cilicaine V (FM)</i>	28
<i>Cilicaine VK (FM)</i>	28
<i>Cilopen VK (GM)</i>	28
<i>Clamoxyl (AL)</i>	30
<i>Clamoxyl Duo (AL)</i>	30
<i>Clamoxyl Duo 400 (AL)</i>	30
<i>Clamoxyl Duo forte (AL)</i>	30

GENERIC/PROPEIETARY INDEX

<i>Clavycillin 875/125 (CR)</i>	30	<i>ERYTHROMYCIN LACTOBIONATE</i>	33
<i>Cleocin (KR)</i>	33	F	
<i>CLINDAMYCIN</i>	33	<i>Fawns and McAllan Proprietary Limited (FM)</i>	38
<i>Clonac 25 (SI)</i>	35	<i>Febridol (GM)</i>	42
<i>Clonac 50 (SI)</i>	35	<i>Feldene (PF)</i>	36
<i>Codalgin Forte (FM)</i>	38	<i>Feldene-D (PF)</i>	36
<i>Codapane Forte (AL)</i>	38	<i>Fenac (AF)</i>	35
<i>CODEINE PHOSPHATE</i>	38	<i>Fenac 25 (AF)</i>	35
<i>CODEINE PHOSPHATE with PARACETAMOL</i>	38	<i>Flagyl (SW)</i>	34
<i>Cogentin (FK)</i>	43	<i>Flagyl S (SW)</i>	34
<i>Comfarol Forte (SZ)</i>	38	<i>Floopen (AS)</i>	29
<i>Cortef (VT)</i>	25	<i>Flubiclox (TS)</i>	29
<i>Cortic-DS 1% (FM)</i>	25	<i>Flucil (AS)</i>	29
<i>Crysanal (MD)</i>	37	<i>FLUCLOXACILLIN</i>	29
<i>Curam (SZ)</i>	30	<i>Fresenius Kabi Australia Pty Limited (PK)</i>	23
<i>Curam Duo (SZ)</i>	30	<i>Fungilin (SI)</i>	21
<i>Curam Duo 500/125 (SZ)</i>	30	G	
<i>Curam Duo Forte 875/125 (SZ)</i>	30	<i>GA Tramadol 50mg (GM)</i>	41
D		<i>GA Tramadol SR 100mg (GM)</i>	41
<i>Dalacin C (PF)</i>	33	<i>GA Tramadol SR 150mg (GM)</i>	41
<i>DBL Metronidazole Intravenous Infusion (HH)</i>	34	<i>GA Tramadol SR 200mg (GM)</i>	42
<i>Depo-Medrol (PF)</i>	26	<i>GA-Amclav 500/125 (GM)</i>	30
<i>Depo-Nisalone (KR)</i>	26	<i>GA-Amclav Forte 875/125 (GM)</i>	30
<i>DIAZEPAM</i>	43	<i>Generic Health Pty Ltd (GQ)</i>	42, 43
<i>Diazepam-GA (GM)</i>	43	<i>GenRx Amoxycillin (GX)</i>	27, 28
<i>Diclocil (BQ)</i>	29	<i>GenRx Amoxycillin and Clavulanic Acid (GX)</i>	30
<i>Diclofenac Sandoz (SZ)</i>	35	<i>GenRx Cefaclor (GX)</i>	32
<i>DICLOFENAC SODIUM</i>	35	<i>GenRx Cefaclor CD (GX)</i>	32
<i>Diclofenac-GA (GM)</i>	35	<i>GenRx Cephalexin (GX)</i>	31
<i>DICLOXACILLIN</i>	29	<i>GenRx Doxycycline (GX)</i>	27
<i>Dicloxsig (SI)</i>	29	<i>GenRx Piroxicam (GX)</i>	36
<i>Difflam (IA)</i>	21	<i>GenRx Tramadol (GX)</i>	41
<i>Dilaudid (MF)</i>	38	<i>GlucaGen Hypokit (NO)</i>	26
<i>Dilaudid-HP (MF)</i>	38	<i>GLUCAGON HYDROCHLORIDE</i>	26
<i>Distaph 250 (AF)</i>	29	<i>GLUCOSE</i>	23
<i>Distaph 500 (AF)</i>	29	<i>GLYCERYL TRINITRATE</i>	24
<i>Dolaforte (CO)</i>	38	H	
<i>Doryx (YN)</i>	27	<i>Hospira Pty Limited (HH)</i>	21, 29, 30, 32, 34, 39, 43
<i>Douglas Cefaclor-CD (GM)</i>	32	<i>HYDROCORTISONE ACETATE</i>	25
<i>Doxsig (SI)</i>	27	<i>HYDROCORTISONE SODIUM SUCCINATE</i>	26
<i>Doxy-100 (GM)</i>	27	<i>HYDROMORPHONE HYDROCHLORIDE</i>	38
<i>DOXYCYCLINE</i>	27	I	
<i>Doxyhexal (SZ)</i>	27	<i>Ialex (LN)</i>	31
<i>Doxylin 100 (AF)</i>	27	<i>Ibilex 125 (AF)</i>	31
<i>Durotram XR (IA)</i>	41	<i>Ibilex 250 (AF)</i>	31
E		<i>Ibilex 500 (AF)</i>	31
<i>E.E.S. 200 (LM)</i>	33	<i>Ibimicyc (TS)</i>	28
<i>E.E.S. 400 Filmtab (LM)</i>	33	<i>IBUPROFEN</i>	36
<i>E.E.S. Granules (LM)</i>	33	<i>Indocid (AS)</i>	35
<i>E-Mycin (AF)</i>	33	<i>INDOMETHACIN</i>	35
<i>E-Mycin 200 (AF)</i>	33	<i>Inza 250 (AF)</i>	36
<i>E-Mycin 400 (AF)</i>	33	<i>Inza 500 (AF)</i>	36
<i>Endone (SI)</i>	40	J	
<i>Eryc (YN)</i>	33	<i>Jurnista (JC)</i>	39
<i>Erythrocin-I.V. (LM)</i>	33		
<i>ERYTHROMYCIN</i>	33		
<i>ERYTHROMYCIN ETHYL SUCCINATE</i>	33		

GENERIC/PROPEIETARY INDEX

K

<i>Kapanol (GK)</i>	40
<i>Karlor CD (LN)</i>	32
<i>Keflex (AS)</i>	31
<i>Keflin Neutral (AS)</i>	30
<i>Keflor (AF)</i>	32
<i>Keflor CD (AF)</i>	32
<i>Kenacort-A10 (SI)</i>	26
<i>KETOPROFEN</i>	36

L

<i>LIGNOCAINE HYDROCHLORIDE</i>	24
<i>Lincocin (PF)</i>	34
<i>LINCOMYCIN</i>	34
<i>Lodam 50 (ZP)</i>	41
<i>Lodam SR 100 (ZP)</i>	41
<i>Lodam SR 150 (ZP)</i>	41
<i>Lodam SR 200 (ZP)</i>	42
<i>LPV (AS)</i>	28
<i>Lycinate (FM)</i>	24

M

<i>Maxamox (SZ)</i>	28
<i>Maxolon (VT)</i>	21
<i>Mayne Pharma Doxycycline (YT)</i>	27
<i>Mayne Pharma Erythromycin (YT)</i>	33
<i>METHYLPREDNISOLONE ACETATE</i>	26
<i>METOCLOPRAMIDE HYDROCHLORIDE</i>	21
<i>Metrogyl 200 (AF)</i>	34
<i>Metrogyl 400 (AF)</i>	34
<i>METRONIDAZOLE</i>	34
<i>METRONIDAZOLE BENZOATE</i>	34
<i>Metronidazole Sandoz (SZ)</i>	34
<i>Metronide 200 (AV)</i>	34
<i>Metronide 400 (AV)</i>	34
<i>Mobilis 10 (AF)</i>	36
<i>Mobilis 20 (AF)</i>	36
<i>Mobilis D-10 (AF)</i>	36
<i>Mobilis D-20 (AF)</i>	36
<i>Mogadon (VT)</i>	44
<i>Momex SR 10 (SI)</i>	39
<i>Momex SR 100 (SI)</i>	40
<i>Momex SR 30 (SI)</i>	39
<i>Momex SR 60 (SI)</i>	40
<i>MORPHINE HYDROCHLORIDE</i>	39
<i>MORPHINE SULFATE</i>	39
<i>Moxiclav Duo 500/125 (SI)</i>	30
<i>Moxiclav Duo Forte 875/125 (SI)</i>	30
<i>MS Contin (MF)</i>	39, 40
<i>MS Contin Suspension 100 mg (MF)</i>	40
<i>MS Contin Suspension 20 mg (MF)</i>	40
<i>MS Contin Suspension 30 mg (MF)</i>	40
<i>MS Contin Suspension 60 mg (MF)</i>	40
<i>MS Mono (MF)</i>	39
<i>Murelax (FM)</i>	44
<i>Mycostatin (FM)</i>	21

N

<i>NALOXONE HYDROCHLORIDE</i>	47
<i>Naloxone Min-I-Jet (CS)</i>	47
<i>Naprosyn (RO)</i>	36
<i>Naprosyn SR1000 (RO)</i>	37
<i>Naprosyn SR750 (RO)</i>	36
<i>NAPROXEN</i>	36
<i>NAPROXEN SODIUM</i>	37
<i>Nilstat (SI)</i>	21, 22
<i>NITRAZEPAM</i>	44
<i>Normison (SI)</i>	44
<i>NYSTATIN</i>	21, 22

O

<i>Ordine 10 (MF)</i>	39
<i>Ordine 2 (MF)</i>	39
<i>Ordine 5 (MF)</i>	39
<i>Orudis (SW)</i>	36
<i>Orudis SR 200 (SW)</i>	36
<i>Oruvail SR (AV)</i>	36
<i>OXAZEPAM</i>	43
<i>OXYCODONE</i>	40
<i>OXYCODONE HYDROCHLORIDE</i>	40
<i>OxyContin (MF)</i>	40, 41
<i>OxyNorm (MF)</i>	40
<i>OxyNorm Liquid 5mg/5mL (MF)</i>	40
<i>Ozcef (RA)</i>	32

P

<i>Panadeine Forte (SW)</i>	38
<i>Panamax (SW)</i>	42, 43
<i>Panamax 240 Elixir (SW)</i>	42
<i>PARACETAMOL</i>	42
<i>Paracetamol Sandoz (SZ)</i>	42, 43
<i>Paralgin (FM)</i>	42, 43
<i>Pfizer Australia Pty Ltd (PF)</i>	24, 47
<i>Pharmacy Choice Paracetamol (YM)</i>	42, 43
<i>PHENOXYMETHYLPENICILLIN</i>	28
<i>PIROXICAM</i>	36
<i>Pramin (AF)</i>	21
<i>PROCAINE PENICILLIN</i>	29
<i>ProCalm (SI)</i>	21
<i>PROCHLORPERAZINE</i>	21
<i>Prochlorperazine-GA (GM)</i>	21
<i>Prodeine Forte (AV)</i>	38
<i>Proladone (PL)</i>	40
<i>PROMETHAZINE HYDROCHLORIDE</i>	21
<i>Proxen SR 1000 (MD)</i>	37
<i>Proxen SR 750 (MD)</i>	36

R

<i>Rancef (RA)</i>	31
<i>Ranmoxy (RA)</i>	28
<i>Ranzepam (RA)</i>	43
<i>Resprim (AF)</i>	32
<i>Resprim Forte (AF)</i>	32
<i>Roxar 150 (SI)</i>	33
<i>Roxar 300 (SI)</i>	33
<i>Roxide (SZ)</i>	33
<i>Roximycin (AF)</i>	33

GENERIC/PROPEIETARY INDEX

<i>ROXITHROMYCIN</i>	33	<i>Tramedo SR 200 (AF)</i>	42
<i>Roxithromycin-GA (GM)</i>	33	<i>TRIAMCINOLONE ACETONIDE</i>	26
<i>Rulide (SW)</i>	33	<i>TRIMETHOPRIM with SULFAMETHOXAZOLE</i>	32
<i>Rulide D (SW)</i>	33		
S		V	
<i>Seprin (SI)</i>	33	<i>Valium (RO)</i>	43
<i>Seprin Forte (SI)</i>	32	<i>Valpam 2 (SI)</i>	43
<i>Serepax (SI)</i>	43, 44	<i>Valpam 5 (SI)</i>	43
<i>Sigmacort (SI)</i>	25	<i>Vancocin CP (AS)</i>	34
<i>SODIUM CHLORIDE</i>	23, 47	<i>VANCOMYCIN</i>	34
<i>SODIUM CHLORIDE with GLUCOSE</i>	23	<i>Vancomycin Sandoz (SZ)</i>	34
<i>Solprin (RC)</i>	42	<i>Vibramycin (PF)</i>	27
<i>Solu-Cortef (PF)</i>	26	<i>Voltaren 100 (NV)</i>	35
<i>Staphylex 250 (AF)</i>	29	<i>Voltaren 25 (NV)</i>	35
<i>Staphylex 500 (AF)</i>	29	<i>Voltaren 50 (NV)</i>	35
<i>Stemetil (SW)</i>	21		
<i>Stemzine (AV)</i>	21	Z	
<i>SULINDAC</i>	35	<i>Zinnat (GK)</i>	32
		<i>Zydol (SI)</i>	41
T		<i>Zydol SR 100 (SI)</i>	41
<i>Tegretol 100 (NV)</i>	43	<i>Zydol SR 150 (SI)</i>	42
<i>Tegretol 200 (NV)</i>	43	<i>Zydol SR 200 (SI)</i>	42
<i>Tegretol CR 200 (NV)</i>	43		
<i>Tegretol CR 400 (NV)</i>	43		
<i>Tegretol Liquid (NV)</i>	43		
<i>Temaze (AF)</i>	44		
<i>TEMAZEPAM</i>	44		
<i>Temtabs (FM)</i>	44		
<i>Teril (AF)</i>	43		
<i>Terry White Chemists Amoxicillin (TW)</i>	27, 28		
<i>Terry White Chemists Amoxicillin and Clavulanic Acid</i> <i>(TW)</i>	30		
<i>Terry White Chemists Cefaclor (TW)</i>	32		
<i>Terry White Chemists Cefaclor CD (TW)</i>	32		
<i>Terry White Chemists Cephalexin (TW)</i>	31		
<i>Terry White Chemists Diclofenac (TW)</i>	35		
<i>Terry White Chemists Doxycycline (TW)</i>	27		
<i>Terry White Chemists Paracetamol (TW)</i>	42, 43		
<i>Terry White Chemists Piroxicam (TW)</i>	36		
<i>Terry White Chemists Roxithromycin (TW)</i>	33		
<i>Terry White Chemists Tramadol (TW)</i>	41		
<i>Terry White Chemists Tramadol SR (TW)</i>	41, 42		
<i>TICARCILLIN with CLAVULANIC ACID</i>	30		
<i>Timentin (GK)</i>	30		
<i>TRAMADOL HYDROCHLORIDE</i>	41, 42		
<i>Tramadol Sandoz (SZ)</i>	41		
<i>Tramadol Sandoz SR (SZ)</i>	41		
<i>Tramahexal (SZ)</i>	42		
<i>Tramahexal SR (SZ)</i>	41, 42		
<i>Tramal (CS)</i>	41		
<i>Tramal 100 (CS)</i>	42		
<i>Tramal SR 100 (CS)</i>	41		
<i>Tramal SR 150 (CS)</i>	42		
<i>Tramal SR 200 (CS)</i>	42		
<i>Tramal SR 50 (CS)</i>	41		
<i>Tramedo (AF)</i>	41		
<i>Tramedo SR 100 (AF)</i>	41		
<i>Tramedo SR 150 (AF)</i>	42		